Can a thyroid hormone rebuild failing hearts?

NCT ID NCT05384847

Completed Disease control Sponsor: Emory University Source: ClinicalTrials.gov ↗

First seen Aug 04, 2026 · Last updated Aug 05, 2026 · Updated 1 time

Summary

This trial asks whether giving the thyroid hormone T3 to people with ischemic heart failure is safe and can improve heart function. Participants with reduced pumping ability will receive oral T3 twice daily for five days under medical supervision, with follow-up over a year. A control group receives standard care without the drug. The study tracks heart rhythm, symptoms, and measures like ejection fraction and walking distance to see if T3 offers benefit.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Thyroid hormone T3 (triiodothyronine)
What this could lead to: If T3 proves safe and improves heart function, it could become a new treatment for ischemic heart failure.
What could go wrong: This is a small early-phase trial, so results may not hold up in larger studies. T3 can affect heart rhythm, so safety is a key concern.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEART FAILURE

Contacts and locations

Locations

Emory University Hospital (EUH)

Atlanta, Georgia, 30322, United States
Emory University Hospital Clinical Research Network

Atlanta, Georgia, 30322, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.